Life (Mar 2023)

Target Trial Emulation Using Hospital-Based Observational Data: Demonstration and Application in COVID-19

  • Oksana Martinuka,
  • Maja von Cube,
  • Derek Hazard,
  • Hamid Reza Marateb,
  • Marjan Mansourian,
  • Ramin Sami,
  • Mohammad Reza Hajian,
  • Sara Ebrahimi,
  • Martin Wolkewitz

DOI
https://doi.org/10.3390/life13030777
Journal volume & issue
Vol. 13, no. 3
p. 777

Abstract

Read online

Methodological biases are common in observational studies evaluating treatment effectiveness. The objective of this study is to emulate a target trial in a competing risks setting using hospital-based observational data. We extend established methodology accounting for immortal time bias and time-fixed confounding biases to a setting where no survival information beyond hospital discharge is available: a condition common to coronavirus disease 2019 (COVID-19) research data. This exemplary study includes a cohort of 618 hospitalized patients with COVID-19. We describe methodological opportunities and challenges that cannot be overcome applying traditional statistical methods. We demonstrate the practical implementation of this trial emulation approach via clone–censor–weight techniques. We undertake a competing risk analysis, reporting the cause-specific cumulative hazards and cumulative incidence probabilities. Our analysis demonstrates that a target trial emulation framework can be extended to account for competing risks in COVID-19 hospital studies. In our analysis, we avoid immortal time bias, time-fixed confounding bias, and competing risks bias simultaneously. Choosing the length of the grace period is justified from a clinical perspective and has an important advantage in ensuring reliable results. This extended trial emulation with the competing risk analysis enables an unbiased estimation of treatment effects, along with the ability to interpret the effectiveness of treatment on all clinically important outcomes.

Keywords